Al-Hajj Muhammad, Wicha Max S, Benito-Hernandez Adalberto, Morrison Sean J, Clarke Michael F
Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. doi: 10.1073/pnas.0530291100. Epub 2003 Mar 10.
Breast cancer is the most common malignancy in United States women, accounting for >40,000 deaths each year. These breast tumors are comprised of phenotypically diverse populations of breast cancer cells. Using a model in which human breast cancer cells were grown in immunocompromised mice, we found that only a minority of breast cancer cells had the ability to form new tumors. We were able to distinguish the tumorigenic (tumor initiating) from the nontumorigenic cancer cells based on cell surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44(+)CD24(-/low)Lineage(-) in eight of nine patients. As few as 100 cells with this phenotype were able to form tumors in mice, whereas tens of thousands of cells with alternate phenotypes failed to form tumors. The tumorigenic subpopulation could be serially passaged: each time cells within this population generated new tumors containing additional CD44(+)CD24(-/low)Lineage(-) tumorigenic cells as well as the phenotypically diverse mixed populations of nontumorigenic cells present in the initial tumor. The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival. Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies.
乳腺癌是美国女性中最常见的恶性肿瘤,每年导致超过40,000人死亡。这些乳腺肿瘤由表型多样的乳腺癌细胞群体组成。利用在免疫缺陷小鼠中培养人乳腺癌细胞的模型,我们发现只有少数乳腺癌细胞具有形成新肿瘤的能力。我们能够根据细胞表面标志物的表达将致瘤性(肿瘤起始)癌细胞与非致瘤性癌细胞区分开来。在9名患者中的8名患者中,我们前瞻性地鉴定并分离出致瘤性细胞为CD44(+)CD24(-/低)谱系(-)细胞。仅有100个具有这种表型的细胞就能在小鼠中形成肿瘤,而数万个具有其他表型的细胞则无法形成肿瘤。致瘤性子群体可以连续传代:每次该群体中的细胞产生新肿瘤时,新肿瘤中都含有额外的CD44(+)CD24(-/低)谱系(-)致瘤性细胞以及初始肿瘤中存在的表型多样的非致瘤性细胞混合群体。前瞻性鉴定致瘤性癌细胞的能力将有助于阐明调节其生长和存活的途径。此外,由于这些细胞驱动肿瘤发展,针对该群体设计的策略可能会带来更有效的治疗方法。